New hope for elderly lymphoma patients: trial tests shorter, targeted treatment
NCT ID NCT06594939
Summary
This study is testing whether adding two newer drugs, mosunetuzumab and polatuzumab vedotin, to a modified chemotherapy regimen can better treat aggressive lymphoma in older adults. The goal is to see if this combination improves the chance of a complete response and allows some patients who respond well early on to receive a shorter course of treatment. The trial will enroll about 31 patients aged 70 and older who are newly diagnosed and have not yet received treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.